Department of Thoracic Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S83-92. doi: 10.1016/j.ejso.2010.06.020. Epub 2010 Jul 3.
Care processes for patients with NSCLC can vary by provider, which may lead to unwanted variation in outcomes. Therefore, in modern health care an increased focus on guideline development and implementation is seen. It is expected that more guideline adherence leads to a higher number of patients receiving optimal treatment for their cancer which could improve overall survival.
The aim of this study was to evaluate variations in treatment patterns and outcomes of patients with NSCLC treated in different (types of) hospitals and regions in the Netherlands. Especially, variation in the percentage of patients receiving the optimal treatment for the stage of their disease, according to the Dutch national guideline of 2004, was analyzed.
All patients with a histological confirmed primary NSCLC diagnosed in the period 2001-2006 in all Dutch hospitals (N = 97) were selected from the population-based Netherlands Cancer Registry. Hospitals were divided in groups based on their region (N = 9), annual volume of NSCLC patients, teaching status and presence of radiotherapy facilities. Stage-specific differences in optimal treatment rates between (groups of) hospitals and regions were evaluated.
In the study period 43 544 patients were diagnosed with NSCLC. The resection rates for stage I/II NSCLC patients increased during the study period, but resection rates varied by region and were higher in teaching hospitals for thoracic surgeons (OR 1.5; 95%CI 1.2-1.9, p = 0.001) and in hospitals with a diagnostic volume of more than 50/year (OR 1.3; 95%CI 1.1-1.5, p = 0.001). Also the use of chemoradiation in stage III patients increased, though marked differences between hospitals in the use of chemoradiation for stage III patients were revealed. Differences in optimal treatment rates between hospitals led to differences in survival.
Treatment patterns and outcome of NSCLC patients in the Netherlands varied by region and the hospital their cancer was diagnosed in. Though resection rates were higher in hospitals training thoracic surgeons, variation between individual hospitals was much more distinct. Hospital characteristics like a high diagnostic volume, teaching status or availability of radiotherapy facilities proved no guarantee for optimal treatment rates.
非小细胞肺癌(NSCLC)患者的护理过程可能因提供者而异,这可能导致治疗结果出现不必要的差异。因此,在现代医疗保健中,越来越重视指南的制定和实施。人们期望更多地遵循指南,从而使更多的患者接受针对其癌症的最佳治疗,这可能会提高整体生存率。
本研究旨在评估荷兰不同(类型的)医院和地区治疗非小细胞肺癌患者的治疗模式和结果的差异。特别是,根据 2004 年荷兰国家指南,分析了根据疾病分期接受最佳治疗的患者比例的变化。
从荷兰癌症登记处选择了 2001-2006 年期间在所有荷兰医院诊断为组织学证实的原发性 NSCLC 的所有患者(N=97)。根据其地区(N=9)、非小细胞肺癌患者的年容量、教学地位和放射治疗设施的存在,将医院分为不同的组。评估了(医院组)和地区之间不同阶段的最佳治疗率差异。
在研究期间,诊断出 43544 名 NSCLC 患者。I/II 期 NSCLC 患者的切除术率在研究期间有所增加,但切除术率因地区而异,胸外科医生教学医院的切除术率更高(OR 1.5;95%CI 1.2-1.9,p=0.001)和每年诊断量超过 50 例的医院(OR 1.3;95%CI 1.1-1.5,p=0.001)。III 期患者接受放化疗的比例也有所增加,但发现医院之间 III 期患者放化疗的使用存在明显差异。医院之间最佳治疗率的差异导致了生存结果的差异。
荷兰非小细胞肺癌患者的治疗模式和结果因地区和诊断癌症的医院而异。尽管在培训胸外科医生的医院中切除术率较高,但个别医院之间的差异更为明显。医院的特点,如高诊断量、教学地位或放射治疗设施的可用性,不能保证最佳治疗率。